Related Experiment Videos
[Cerebral tumors and neoangiogenesis ]
1Service de Neurochirurgie A, Hôpital Pierre Wertheimer, Université Lyon I.
Neuro-Chirurgie
|December 22, 1999
Summary
Antiangiogenesis agents show promise in controlling tumor growth by inhibiting new blood vessel formation. Preclinical and ongoing clinical trials are evaluating their potential as cancer therapies.
Area of Science:
- Oncology
- Vascular Biology
- Cancer Research
Context:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth.
- Tumor progression is regulated by a balance of proangiogenic and antiangiogenic factors.
- Targeting angiogenesis offers a novel strategy for cancer treatment.
Purpose:
- To review the role of angiogenesis in tumor development.
- To explore the potential of antiangiogenesis agents in cancer therapy.
- To present an overview of preclinical and clinical trials involving antiangiogenesis agents.
Summary:
- Preclinical studies demonstrate that inhibiting proangiogenic factors (e.g., VEGF, FGF) or using antiangiogenic factors can impede tumor growth in animal models.
- Endostatin, a natural angiogenesis inhibitor, has shown potential for complete tumor regression in preliminary studies.
- Clinical trials are underway to assess the efficacy of antiangiogenesis agents like Marismastat and Thalidomide in neurooncology and general cancer treatment.
Impact:
- Antiangiogenesis therapies represent a promising avenue for cancer treatment, potentially offering new therapeutic strategies.
- Ongoing clinical trials will determine the integration of these agents into established cancer treatment protocols.
- Further research is essential to fully understand the clinical utility and optimal application of antiangiogenesis agents in oncology.